<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039892</url>
  </required_header>
  <id_info>
    <org_study_id>3D185-C-002</org_study_id>
    <nct_id>NCT05039892</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma</brief_title>
  <official_title>An Open-label, Single Arm, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3D Medicines (Beijing) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3D Medicines</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate the efficacy of 3D185 in subjects with&#xD;
      advanced/metastatic cholangiocarcinoma with FGFR2 Gene Alterations who have failed at least 1&#xD;
      previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2022</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
    <description>defined as the proportion of subjects who achieved a confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 as assessed by investigators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>24 months</time_frame>
    <description>DoR is defined as the time from the date of first CR or PR based on RECIST v1.1 to the date of first documented progressive disease based on RECIST v1.1 or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>defined as the proportion of subjects who achieve a confirmed complete response (CR) or partial response (PR) or stable disease (SD) based on RECIST v1.1 as assessed by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS is defined as the time from the date of first study dose to disease progression based on RECIST v1.1 or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS is defined as the date of first study dose to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3D185 Plasma concentration</measure>
    <time_frame>24 months</time_frame>
    <description>The pharmacokinetic and pharmacodynamics assessments will be analyzed descriptively and presented in appropriate tables or figures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum phosphate levels</measure>
    <time_frame>24 months</time_frame>
    <description>The pharmacokinetic and pharmacodynamics assessments will be analyzed descriptively and presented in appropriate tables or figures.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cholangiocarcinoma,Adult</condition>
  <arm_group>
    <arm_group_label>All eligible subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3D185</intervention_name>
    <description>All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.</description>
    <arm_group_label>All eligible subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed cholangiocarcinoma.&#xD;
&#xD;
          2. Documented disease progression following at least one previous systemic cancer therapy&#xD;
&#xD;
          3. Tumor assessment for FGF/FGFR gene alteration status.&#xD;
&#xD;
          4. Have measurable disease according to RECIST v1.1&#xD;
&#xD;
          5. ECOG Performance Status ≤ 2&#xD;
&#xD;
          6. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously received selective FGFR inhibitor therapy.&#xD;
&#xD;
          2. History of and/or current evidence of ectopic mineralization/calcification, including&#xD;
             but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting&#xD;
             calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.&#xD;
&#xD;
          3. Have any of the following eye diseases/conditions: 1) history of retinal pigment&#xD;
             epithelial detachment (RPED); 2) history of laser treatment or intraocular injection&#xD;
             for macular degeneration; 3) history of dry or wet age-related macular degeneration;&#xD;
             4) history of retinal vein occlusion (RVO); 5) history of retinal degenerative&#xD;
             diseases; 6) history of chorioretinal lesions..&#xD;
&#xD;
          4. Received CYP3A4 and/or CYP2C8 strong inhibitors or CYP3A4 strong inducers within 14&#xD;
             days prior to the first dose and subject who need to continue using these drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>silong xiang, MD</last_name>
    <phone>( 86)15901312398</phone>
    <email>silong.xiang@3d-medicines.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

